#1453P

A Phase Ib Study of AN0025 in Combination With Definitive Chemoradiotherapy (dCRT) in Unresectable Locally Advanced or Locally Recurrent Esophageal Cancer (EC)

N. Bi¹, F. Liu², Y. Hu³, W. Wang⁴, W. Liu¹, R. Liu⁵, Y. Liu², P. Zhang², C. Zhao⁵, J. Chen², L. Luo³, Z. Huang³, M. Gu⁶, S. Lu⁶, X. Song⁶, T. Zhao⁶, Y. Wang⁶, H. Liang⁶, J. Xu^{5,*}

¹Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Radiotherapy, The First Medical Center, Chinese PLA General Hospital, Beijing, China, ³Department of Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ⁴Department of Gastroenterology and Urology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, ⁶Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China, ⁶Adlai Nortye Biopharma Co., Ltd., Hangzhou, China, *Corresponding author

BACKGROUND

AN0025 is a highly selective and potent antagonist of the prostaglandin E2 (PGE2) receptor 4 (EP4) (PGE2-EP4). It demonstrates antitumor activity by modulating the accumulation and function of immunosuppressive myeloid cells including tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) in the tumor microenvironment^{1,2,3}

lonizing radiation triggers the massive production of PGE2 during apoptosis in tumor cells, while the PGE2-EP4 signaling pathway contributes to the generation and maintenance of the immunosuppressive properties of the tumor microenvironment^{4,5}. Therefore, the combination of AN0025 which inhibits PGE2-EP4 activity with radiotherapy (RT) is proposed to exert synergistic anti-tumor effect. Preclinical studies have demonstrated that combining AN0025 with RT exhibits strong antitumor activity, and data from animal models indicate that this combination may also promote the development of an immune memory antitumor response⁶

Additionally, the combination of AN0025 with CRT as neoadiuvant therapy has shown encouraging antitumor efficacy in locally advanced rectal cancer in a prior Ph1b clinical trial (NCT03152370). In this trial, a complete response (CR) rate of 36% was observed (4 [26.7%] of 15 patients who underwent surgery achieved pathological CR and 5 [20%] of 25 patients achieved clinical CR), further supporting the development of AN0025 in combination with CRT



METHODS

Figure 2: Overall Study Design



- Squamous cell carcinoma or adenocarcinoma
- radiotherapy in the esophageal region suitable for dCRT



Key objectives

safety and tolerability: DLT, MTD and/or RP2D Primary:

ndary: preliminary efficacy per RECIST 1.1, including CRR, ORR, DCR, PFS, DOR, OS; PK profile

Exploratory: correlation between selected pharmacodynamic biomarkers and efficacy; een the exposure of AN0025/metabolites and parameters related to clinical



RESULTS

Clinical trial information: NCT05191667. The study is being conducted in 3 research sites in China

Data were analyzed based on data cutoff of 23 Aug 2024

Table 1: Patient Demographics and Baseline Characteristics

Number of patients		250 mg n=5	500 mg n=7	All n=12
Age in years, median (range)		61 (52, 64)	64 (56, 70)	61.5 (52, 70)
Race	Asian	5 (100%)	7 (100%)	12 (100%)
Sex	Male	5 (100%)	6 (86%)	11 (92%)
	Female	0	1 (14%)	1 (8%)
ECOG PS	0	5 (100%)	5 (71%)	10 (83%)
	1	0	2 (29%)	2 (17%)
Tumor category	Locally advanced	5 (100%)	6 (86%)	11 (92%)
	Locally recurrent	0	1 (14%)	1 (8%)
Histology	Squamous cell carcinoma	5 (100%)	7 (100%)	12 (100%)
T stage	T2	1 (20%)	1 (14%)	2 (17%)
	T3-T4b	4 (80%)	6 (86%)	10 (83%)
N stage	N1-2	4 (80%)	6 (86%)	10 (83%)
	N3	1 (20%)	1 (14%)	2 (17%)
M stage	M0	5 (100%)	6 (86%)	11 (92%)
	M1	0	1 (14%)	1 (8%)
Measurable disease	Yes	2 (40%)	6 (86%)	8 (67%)
	No	3 (60%)	1 (14%)	4 (33%)

Safety profile

- Twelve (100%) patients experienced at least 1 treatment-emergent adverse event (TEAE), 10 (83%) patients experienced at least 1 TEAE with Grade \geq 3.
- Eleven (92%) patients experienced at least 1 AN0025-related AE, 2 (17%) patients experienced at least 1 Grade ≥ 3 AN0025-related AE.
- Seven (58%) patients experienced 9 serious adverse events (SAEs), none of which were deemed related to AN0025
- Two (17%) patients experienced AEs leading to dose reduction of chemotherapy. No patients experienced AEs leading to dose reduction of radiotherapy or AN0025.
- Nine (75%), 5 (42%), and 3 (25%) patients experienced at least 1 AE leading to dose interruption of AN0025, chemotherapy, and radiotherapy, respectively.
- One (8%) patient had AE that led to discontinuation of radiotherapy. No patients had AEs that led to discontinuation of AN0025 or chemotherapy.
- No DLT occurred at either dose level, and the maximum tolerated dose (MTD) was not reached.

Table 2: AN0025-Relate TRAEs, patients (%) Occurred in ≥ 2 patients with Weight decreased Anemia White blood cell count decreased Diarrhea Asthenia Esophageal fistula

umber (%) of patients

Complete response (CR)		
Partial response (PR)		
Stable disease (SD)		
Progressive disease (PD)		
Non-CR/non-PD		
Confirmed overall response r (cORR) **		
Unconfirmed overall respons rate (uORR) **		
Disease control rate (DCR)		
N/A = not applicable. *One p uORR is 100% (2/2) at 250 m		
Among the 8 patients w		

- ORR of 75% (6/8).
- post-surgery pathology



(%

ne

bas

÷

m B

ed AEs								
250 mg n=5		500 mg n=7		All n=12				
Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3			
5 (100%)	1 (20%)	6 (86%)	1 (14%)	11 (92%)	2 (17%)			
any grade or in \geq 1 patient with Grade \geq 3								
3 (60%)	1 (20%)	3 (43%)	0	6 (50%)	1 (8%)			
4 (80%)	0	0	0	4 (33%)	0			
3 (60%)	0	0	0	3 (25%)	0			
2 (40%)	0	1 (14%)	0	3 (25%)	0			
1 (20%)	0	1 (14%)	0	2 (17%)	0			
0	0	1 (14%)	1 (14%)	1 (8%)	1 (8%)			

Table 3: Preliminary Efficacy: Best Overall Response (BOR) per RECIST v1.1

	Measurable disease at baseline n = 8	No measurable disease at baseline n = 4 ***	All n = 12
	1 (13%)	0	1 (8%)
	6* (75%)	N/A	6* (50%)
	1 (13%)	N/A	1 (8%)
	0	1 (25%)	1 (8%)
	N/A	3 (75%)	3 (25%)
e	6 (75%)		
	7 (88%)		
	8 (100%)	3 (75%)	11 (92%)

atient had an unconfirmed PR. **cORR is 50% (1/2) at 250 mg and 83% (5/6) at 500 mg, ng and 83% (5/6) at 500 mg. ***Primary esophageal lesions are non-measu

vith measurable disease at baseline, 1 (12%) achieved confirmed CR, 6 achieved PR, including 5 confirmed PRs, giving an unconfirmed overall response rate (ORR) of 88% (7/8) and a confirmed

Among the 4 patients without measurable disease at baseline, 3 (75%) achieved non-CR/non-PD, including 1 patient who transformed to be operable and achieved pathologic complete response (pCR) confirmed by

The disease control rate (DCR) was 92% (11/12).

Figure 4: Best Percentage Change in Target Lesions

Best change from baseline is available for 8 patients who had measurable lesions at baseline and had at least one post-treatment tumor assessment It is measured as largest percentage

reduction in sum of longest diameters of

the target lesions.



Figure 5: Time on Treatment and Tumor Response Assessment

- The median follow-up was 19.3 months, with 7 patients remaining on study treatment and a maximum time on treatment of 29.9 months.
- The median progression-free survival (PES) was not reached with an 18-month PES rate of 73% The 18month overall survival (OS) rate was 82%

Figure 6: Pharmacokinetics Profile of AN0025 Monotherapy in the Maintenance Phase



Overall, the exposure of AN0025 increased proportionally between 250 mg to 500 mg.

The exposure of AN0025 largely overlapped between the 250 mg and 500 mg QD doses on Day 1 of the AN0025 monotherapy maintenance phase (the first dose); however, dose proportionality was observed on Day 8 of the maintenance phase at the steady state.

CONCLUSIONS

- AN0025 in combination with dCRT was well tolerated in both 250 mg and 500 mg QD dose levels in Chinese patients with unresectable locally advanced/locally recurrent esophageal cancer. No DLTs were observed.
- AN0025 PK approached linearity at both 250 mg and 500 mg QD.
- · Preliminary efficacy results are encouraging and support the development of AN0025 as an immune modulator with CRT.

References

L Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, et al. Functional haracterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced rom peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.

. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor- derived

Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor- derived prostaglandina-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clinical Cancer Res. 2014;20(15):4096.
Majumder M, Xin X, Liu L, Girish GV, Lala PK. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish anglogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci. 2014;105(9):1142.
Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015; 162(6):1257.
Allen CP, Tinganelli W, Sharma N, Nie J, Sicard C, Natale F, et al. DAN Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and Ulticity L7 Turbing Derivations.

Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Rediation. Front Oncol. 2015;5::260. 6. Bao X, Albu DI, Huang KC, Wu J, Twine N, Nomoto K, et al. Combination of a novel EP4 antagonist E7046 and radiation therapy promotes anti-tumor immune response and tumor rejection in preclinical tumor models. Int J Radiat Oncol Biol Phys. 2016;96(2):S128. 7. Wyrwicz L, Saunders MP, Hall M, Ng J, Bhagawati Prasad V, Lautermilch N, et al. A phase Ib study of E7046 (AN0025) in combination with radiotherapy/chemoradiotherapy (RT/CRT) in preoperative treatment of rectal cancer. Ann. Oncol. 2019;30(5):v205.

Acknowledgments

We thank the patients and their caregivers for participating in this trial. We also thank the investigators and their support staff who generously participated in this work. This study is sponsored by Adlai Nortye Biopharma Co., Ltd.

Disclosure

N. Bi, F. Liu, Y. Hu, W. Wang, W. Liu, R. Liu, Y. Liu, P. Zhang, C. Zhao, . Luo, Z. Huang, and J. Xu have nothing to disclose. M. Gu, S. Lu, X Zhao, Y. Wang, and H. Liang: Full-time employees of Adlai Nortye S. Lu and X. Song: Shareholders of Adlai Nortye.

